Wednesday, January 31, 2018

Seattle Genetics To Acquire Cascadian Therapeutics For $614M

Seattle Genetics and fellow Seattle biotech Cascadian Therapeutics said on Wednesday that the two have entered into an agreement, where Seattle Genetics will acquire Cascadian for $614M in cash. Cascadian is a developer of treatments for metastatic breast cancer.